Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2018 Dec 28

PMID 30588192

Citations 17

Authors

Satoshi Yokoyama

Yuki Tanaka

Kazuki Nakagita

Kouichi Hosomi

Mitsutaka Takada

Affiliations

Soon will be listed here.

Abstract

A historical cohort analysis of the Japan medical data center (JMDC) claims databases was performed to compare the incidence rates of bleeding events with warfarin (WF) versus direct oral anticoagulant (DOAC) treatment in patients with non-valvular atrial fibrillation. The aim of this study is to clarify the risk factors for bleeding events in younger patients newly treated with WF or DOAC in clinical practice setting. Patients who newly initiated WF or DOAC treatment from April 2012 to March 2015 were selected from the JMDC claims database. A 1:1 propensity score matching analysis was used for new users of WF or DOAC. Kaplan-Meier curves were generated to depict the time to bleeding event (total bleeding events, gastrointestinal hemorrhage, and intracranial hemorrhage) during the follow-up period. Cox proportional regression models were used to estimate the hazard ratios for total bleeding events caused by oral anticoagulants. Overall, 2,046 patients (503 WF and 1,543 DOAC) were included. After applying propensity score matching, Kaplan-Meier analysis of the WF and DOAC groups displayed comparable incidences of total bleeding events, gastrointestinal hemorrhage, and intracranial hemorrhage. Cox proportional hazards modeling showed that the use of WF was not associated with total bleeding events compared with DOAC (hazard ratio: 1.21, 95% confidence interval: 0.93-1.54, = 0.15). This historical cohort study using a claims database indicates that the bleeding risk of DOAC was comparable to that of WF in Japanese younger population.

Citing Articles

Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality.

Fan H, Bessada Y, Coleman C Res Pract Thromb Haemost. 2025; 9(1):102688.

PMID: 40060367 PMC: 11889373. DOI: 10.1016/j.rpth.2025.102688.

Amelioration of obsessive-compulsive disorder by intracellular acidification of cortical neurons with a proton pump inhibitor.

Hatakama H, Asaoka N, Nagayasu K, Shirakawa H, Kaneko S Transl Psychiatry. 2024; 14(1):27.

PMID: 38228604 PMC: 10791614. DOI: 10.1038/s41398-024-02731-3.

Sex differences in associations between creatinine and cystatin C-based kidney function measures with stroke and major bleeding.

Lees J, De La Mata N, Sullivan M, Wyld M, Rosales B, Cutting R Eur Stroke J. 2023; 8(3):756-768.

PMID: 37641551 PMC: 10465308. DOI: 10.1177/23969873231173282.

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients.

Diamond A, Bensken W, Vu L, Dong W, Koroukian S, Caimi P JACC CardioOncol. 2023; 5(2):233-243.

PMID: 37144107 PMC: 10152196. DOI: 10.1016/j.jaccao.2023.02.001.

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.

Wang Y, Cavallari L, Brown J, Thomas C, Winterstein A JAMA Netw Open. 2023; 6(4):e238585.

PMID: 37067798 PMC: 10111179. DOI: 10.1001/jamanetworkopen.2023.8585.

References

Gage B, Waterman A, Shannon W, Boechler M, Rich M, Radford M . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22):2864-70. DOI: 10.1001/jama.285.22.2864. View

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

Kimura S, Sato T, Ikeda S, Noda M, Nakayama T . Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010; 20(5):413-9. PMC: 3900837. DOI: 10.2188/jea.je20090066. View

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

Camm A, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser S . 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21):2719-47. DOI: 10.1093/eurheartj/ehs253. View

Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez J, Valdes M . The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013; 62(23):2199-204. DOI: 10.1016/j.jacc.2013.08.1623. View

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2013; 383(9921):955-62. DOI: 10.1016/S0140-6736(13)62343-0. View

10.

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):e199-267. PMC: 4676081. DOI: 10.1161/CIR.0000000000000041. View

11.

Abraham N, Singh S, Alexander G, Heien H, Haas L, Crown W . Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015; 350:h1857. PMC: 4413863. DOI: 10.1136/bmj.h1857. View

12.

Chang H, Zhou M, Tang W, Alexander G, Singh S . Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015; 350:h1585. PMC: 4413867. DOI: 10.1136/bmj.h1585. View

13.

Spivey C, Qiao Y, Liu X, Mardekian J, Parker R, Phatak H . Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2015; 21(7):596-606. PMC: 10398305. DOI: 10.18553/jmcp.2015.21.7.596. View

14.

Potpara T, Lip G . Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. Prog Cardiovasc Dis. 2015; 58(2):177-94. DOI: 10.1016/j.pcad.2015.07.003. View

15.

Suzuki S, Otsuka T, Sagara K, Semba H, Kano H, Matsuno S . Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation　- Shinken Database Analysis. Circ J. 2016; 80(3):639-49. DOI: 10.1253/circj.CJ-15-1237. View

16.

Kachroo S, Hamilton M, Liu X, Pan X, Brixner D, Marrouche N . Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation. Am J Manag Care. 2016; 22(1):e1-8. View

17.

Camm A, Accetta G, Ambrosio G, Atar D, Bassand J, Berge E . Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2016; 103(4):307-314. PMC: 5293840. DOI: 10.1136/heartjnl-2016-309832. View

18.

Abe M, Ogawa H, Ishii M, Masunaga N, Esato M, Chun Y . Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). Am J Cardiol. 2017; 119(8):1229-1237. DOI: 10.1016/j.amjcard.2017.01.005. View

19.

Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun Y, Tsuji H . Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　- Fushimi AF Registry. Circ J. 2017; 81(9):1278-1285. DOI: 10.1253/circj.CJ-16-1337. View

20.

Manzoor B, Lee T, Sharp L, Walton S, Galanter W, Nutescu E . Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy. 2017; 37(10):1221-1230. DOI: 10.1002/phar.1989. View